Atrial Fibrillation in Congestive Heart Failure: Current Management

Cardiology Clinics

Volumn 27, Issue 1, 2009, Pages 79-93

  Boyle, Noel G ^a   Shivkumar, Kalyanam ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Atrial remodeling; Catheter ablation; Congestive heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIINFLAMMATORY AGENT; CANDESARTAN; CARVEDILOL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOFETILIDE; DRONEDARONE; ENALAPRIL; FISH OIL; FLECAINIDE; IBUTILIDE; PLACEBO; PROPAFENONE; RAMIPRIL; SOTALOL; SPIRONOLACTONE; TRANDOLAPRIL; WARFARIN;

ANTICOAGULANT THERAPY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DEVICE; DISEASE PREDISPOSITION; ELECTROCARDIOGRAPHY; EXERCISE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOLTER MONITORING; HUMAN; KIDNEY FAILURE; LEFT ATRIAL APPENDAGE OCCLUDER DEVICE; PRIORITY JOURNAL; PROPHYLAXIS; RADIOFREQUENCY ABLATION; REVIEW; RISK ASSESSMENT; SINUS RHYTHM; THROMBOEMBOLISM; TORSADE DES POINTES; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; ELECTRIC COUNTERSHOCK; HEART FAILURE; HEART RATE; HUMANS; TREATMENT OUTCOME;

EID: 58149163132     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2008.09.016     Document Type: Review

References (98)

1. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 337 19 (1997) 1360-1369
2. Heart and stroke facts 2008.
3. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285 18 (2001) 2370-2375
4. Wang T.J., Larson M.G., Levy D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart study. Circulation 107 23 (2003) 2920-2925
5. Maisel W.H., and Stevenson L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91 6A (2003) 2D-8D
6. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 23 (2002) 1825-1833
7. Allessie M., Ausma J., and Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 54 2 (2002) 230-246
8. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 415 6868 (2002) 219-226
9. Nattel S, Shiroshita-Takeshita A, Brundel BJ, et al. Mechanisms of atrial fibrillation: lessons from animal models. Prog Cardiovasc Dis;48(1):9-28.
10. Nattel S., and Opie L.H. Controversies in atrial fibrillation. Lancet 367 9506 (2006) 262-272
11. Cha T.J., Ehrlich J.R., Zhang L., et al. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation 109 3 (2004) 412-418
12. Li D., Shinagawa K., Pang L., et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104 21 (2001) 2608-2614
13. Yeh Y.-H., Wakili R., Qi X.-Y., et al. Calcium handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol 1 2 (2008) 93-102
14. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the management of patients with atrial fibrillation): developed in collaboration
15. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 12 (2005) e154-e235
16. Hart R.G., Benavente O., McBride R., et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131 7 (1999) 492-501
17. van Walraven C., Hart R.G., Wells G.A., et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 163 8 (2003) 936-943
18. Rietbrock S., Heeley E., Plumb J., et al. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age > 75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 156 1 (2008) 57-64
19. Freudenberger R.S., Hellkamp A.S., Halperin J.L., et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 115 20 (2007) 2637-2641
20. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 6 Suppl (2008) 546S-592S
21. Connolly S.J., Eikelboom J., O'Donnell M., et al. Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation 116 4 (2007) 449-455
22. Sick P.B., Schuler G., Hauptmann K.E., et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol 49 13 (2007) 1490-1495
23. Stollberger C., Schneider B., and Finsterer J. Serious complications from dislocation of a Watchman left atrial appendage occluder. J Cardiovasc Electrophysiol 18 8 (2007) 880-881
24. Hart R.G., and Halperin J.L. Atrial fibrillation and stroke: concepts and controversies. Stroke 32 3 (2001) 803-808
25. Demircan C., Cikriklar H.I., Engindeniz Z., et al. Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation. Emerg Med J 22 6 (2005) 411-414
26. Khand A.U., Rankin A.C., Martin W., et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?. J Am Coll Cardiol 42 11 (2003) 1944-1951
27. Olshansky B., Rosenfeld L.E., Warner A.L., et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 43 7 (2004) 1201-1208
28. Weerasooriya R., Davis M., Powell A., et al. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 41 10 (2003) 1697-1702
29. Bradley D.J., and Shen W.K. Atrioventricular junction ablation combined with either right ventricular pacing or cardiac resynchronization therapy for atrial fibrillation: the need for large-scale randomized trials. Heart Rhythm 4 2 (2007) 224-232
30. McGavigan A.D., and Mond H.G. Selective site ventricular pacing. Curr Opin Cardiol 21 1 (2006) 7-14
31. Koneru J.N., and Steinberg J.S. Cardiac resynchronization therapy in the setting of permanent atrial fibrillation and heart failure. Curr Opin Cardiol 23 1 (2008) 9-15
32. Valls-Bertault V., Fatemi M., Gilard M., et al. Assessment of upgrading to biventricular pacing in patients with right ventricular pacing and congestive heart failure after atrioventricular junctional ablation for chronic atrial fibrillation. Europace 6 5 (2004) 438-443
33. Doshi R.N., Daoud E.G., Fellows C., et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 16 11 (2005) 1160-1165
34. Occhetta E., Bortnik M., Magnani A., et al. Prevention of ventricular desynchronization by permanent para-Hisian pacing after atrioventricular node ablation in chronic atrial fibrillation: a crossover, blinded, randomized study versus apical right ventricular pacing. J Am Coll Cardiol 47 10 (2006) 1938-1945
35. Mittal S., Ayati S., Stein K.M., et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 101 11 (2000) 1282-1287
36. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J 18 4 (1997) 649-654
37. Volgman A.S., Carberry P.A., Stambler B., et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 31 6 (1998) 1414-1419
38. Alboni P., Botto G.L., Baldi N., et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 351 23 (2004) 2384-2391
39. Camm A.J. Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol 127 3 (2008) 299-306
40. Vardas P.E., Kochiadakis G.E., Igoumenidis N.E., et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest 117 6 (2000) 1538-1545
41. Klein A.L., Grimm R.A., Murray R.D., et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344 19 (2001) 1411-1420
42. Khand A.U., Rankin A.C., Kaye G.C., et al. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J 21 8 (2000) 614-632
43. Roy D., Talajic M., Dorian P., et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342 13 (2000) 913-920
44. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 42 1 (2003) 20-29
45. Singh B.N., Singh S.N., Reda D.J., et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352 18 (2005) 1861-1872
46. Doval H.C., Nul D.R., Grancelli H.O., et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 344 8921 (1994) 493-498
47. Singh S.N., Fletcher R.D., Fisher S.G., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med 333 2 (1995) 77-82
48. Torp-Pedersen C., Moller M., Bloch-Thomsen P.E., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 341 12 (1999) 857-865
49. Banchs J.E., Wolbrette D.L., Samii S.M., et al. Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter. J Interv Card Electrophysiol 23 (2008) 111-115
50. Singh B.N., Connolly S.J., Crijns H.J., et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 357 10 (2007) 987-999
51. Hohnloser S.H., Connolly S.J., Crijns H.J., et al. Rationale and design of ATHENA: a placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol 19 1 (2008) 69-73
52. Kober L., Torp-Pedersen C., McMurray J.J., et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358 25 (2008) 2678-2687
53. Ezekowitz M.D. Maintaining sinus rhythm-making treatment better than the disease. N Engl J Med 357 10 (2007) 1039-1041
54. Hohnloser S.H., Kuck K.H., and Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356 9244 (2000) 1789-1794
55. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 23 (2002) 1834-1840
56. Carlsson J., Miketic S., Windeler J., et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41 10 (2003) 1690-1696
57. Opolski G., Torbicki A., Kosior D.A., et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest 126 2 (2004) 476-486
58. Chung M.K. Randomized trials of rate vs. rhythm control for atrial fibrillation. J Interv Card Electrophysiol 10 Suppl 1 (2004) 45-53
59. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 25 (2008) 2667-2677
60. Freudenberger R.S., Wilson A.C., and Kostis J.B. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol 100 2 (2007) 247-252
61. Cain M.E., and Curtis A.B. Rhythm control in atrial fibrillation-one setback after another. N Engl J Med 358 25 (2008) 2725-2727
62. Deedwania P.C., Singh B.N., Ellenbogen K., et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 98 23 (1998) 2574-2579
63. Pedersen O.D., Brendorp B., Elming H., et al. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study. Card Electrophysiol Rev 7 3 (2003) 220-224
64. Corley S.D., Epstein A.E., DiMarco J.P., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 109 12 (2004) 1509-1513
65. Ehrlich J.R., Hohnloser S.H., and Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 27 5 (2006) 512-518
66. Pedersen O.D., Bagger H., Kober L., et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100 4 (1999) 376-380
67. Vermes E., Tardif J.C., Bourassa M.G., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107 23 (2003) 2926-2931
68. Ueng K.C., Tsai T.P., Yu W.C., et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 24 23 (2003) 2090-2098
69. Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 11 (2005) 1832-1839
70. Salehian O., Healey J., Stambler B., et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J 154 3 (2007) 448-453
71. Tveit A., Grundvold I., Olufsen M., et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 120 1 (2007) 85-91
72. Connolly S., Yusuf S., Budaj A., et al. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J 151 6 (2006) 1187-1193
73. Murray K.T., Mace L.C., and Yang Z. Nonantiarrhythmic drug therapy for atrial fibrillation. Heart Rhythm 4 3 Suppl (2007) S88-S90
74. Burstein B., and Nattel S. Atrial structural remodeling as an antiarrhythmic target. J Cardiovasc Pharmacol 52 1 (2008) 4-10
75. Heidbuchel H. A paradigm shift in treatment for atrial fibrillation: from electrical to structural therapy?. Eur Heart J 24 23 (2003) 2077-2078
76. Dorian P., and Singh B.N. Upstream therapies to prevent atrial fibrillation. Eur Heart J Suppl 10 Suppl H (2008) H11-H31
77. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 21 (2004) 2140-2150
78. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 15 (2005) 1539-1549
79. Leclercq C., Walker S., Linde C., et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 23 22 (2002) 1780-1787
80. Gasparini M., Auricchio A., Regoli F., et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol 48 4 (2006) 734-743
81. Gasparini M., Auricchio A., Metra M., et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 29 13 (2008) 1644-1652
82. Khadjooi K., Foley P.W., Chalil S., et al. Long-term effects of cardiac resynchronisation therapy in patients with atrial fibrillation. Heart 94 7 (2008) 879-883
83. Steinberg J.S. Desperately seeking a randomized clinical trial of resynchronization therapy for patients with heart failure and atrial fibrillation. J Am Coll Cardiol 48 4 (2006) 744-746
84. Hoppe U.C., Casares J.M., Eiskjaer H., et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 114 1 (2006) 18-25
85. Lellouche N., De Diego C., Vaseghi M., et al. Cardiac resynchronization therapy response is associated with shorter duration of atrial fibrillation. Pacing Clin Electrophysiol 30 11 (2007) 1363-1368
86. Yannopoulos D., Lurie K.G., Sakaguchi S., et al. Reduced atrial tachyarrhythmia susceptibility after upgrade of conventional implanted pulse generator to cardiac resynchronization therapy in patients with heart failure. J Am Coll Cardiol 50 13 (2007) 1246-1251
87. Padeletti L., Muto C., Maounis T., et al. Atrial fibrillation in recipients of cardiac resynchronization therapy device: 1-year results of the randomized MASCOT trial. Am Heart J 156 3 (2008) 520-526
88. Haissaguerre M., Jais P., Shah D.C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339 10 (1998) 659-666
89. Calkins H., Brugada J., Packer D.L., et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) task force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 4 6 (2007) 816-861
90. Spragg D.D., Dalal D., Cheema A., et al. Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol 19 6 (2008) 627-631
91. Chen M.S., Marrouche N.F., Khaykin Y., et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 43 6 (2004) 1004-1009
92. Hsu L.F., Jais P., Sanders P., et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351 23 (2004) 2373-2383
93. Gentlesk P.J., Sauer W.H., Gerstenfeld E.P., et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 18 1 (2007) 9-14
94. Efremidis M., Sideris A., Xydonas S., et al. Ablation of atrial fibrillation in patients with heart failure: reversal of atrial and ventricular remodelling. Hellenic J Cardiol 49 1 (2008) 19-25
95. Lutomsky B.A., Rostock T., Koops A., et al. Catheter ablation of paroxysmal atrial fibrillation improves cardiac function: a prospective study on the impact of atrial fibrillation ablation on left ventricular function assessed by magnetic resonance imaging. Europace 10 5 (2008) 593-599
96. Cleland J.G., Coletta A.P., Abdellah A.T., et al. Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty. Eur J Heart Fail 9 1 (2007) 92-97
97. Pappone C., Augello G., Sala S., et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 48 11 (2006) 2340-2347
98. Nair G.M., Nery P.B., Diwakaramenon S., et al. A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. J Cardiovasc Electrophysiol September 3 (2008) [Epub ahead of print]